Auna’s New Data Reveals Strong Growth in Latin American Healthcare

LUXEMBOURG – April 17, 2026 – Auna S.A. (NYSE: AUNA), a major healthcare platform in Latin America, has pulled back the curtain on its operational engine, releasing a detailed set of preliminary Key Performance Indicators (KPIs) for the first quarter of 2026. This move, part of a new commitment to quarterly operational reporting, provides an unprecedentedly granular view of its performance across Mexico, Peru, and Colombia, revealing significant growth in specialized care and highlighting a strategic push for greater investor transparency.

The data paints a picture of a company capitalizing on rising healthcare demand, with notable gains in oncology services, health plan memberships, and hospital capacity utilization. While the information is preliminary, it offers a robust snapshot of Auna's market penetration and operational efficiency in three of the region's most dynamic healthcare markets.

A New Era of Transparency for Investors

For investors and market analysts, Auna's decision to publish quarterly operational metrics is as significant as the numbers themselves. By committing to this level of regular disclosure, the company is aiming to provide a clearer, more frequent understanding of its business rhythm, moving beyond the traditional financial reports to showcase the underlying drivers of its performance.

This enhanced transparency appears to be a strategic response to a market that values clarity. While Auna's stock holds a consensus "Hold" rating from analysts, some see significant untapped potential. Earlier this year, Jefferies initiated coverage with a "Buy" rating and a $9.00 price target, citing a belief that the company was deeply discounted following underperformance in 2025. The firm anticipated a re-acceleration of growth as operations, particularly in Mexico, began to normalize.

The new KPIs offer tangible evidence to support such optimism. With a price-to-earnings ratio that is considerably lower than the medical sector average, Auna's leadership is betting that consistent, detailed operational data will help bridge the gap between its current valuation and its growth trajectory. The numbers provide a narrative of progress that quarterly earnings calls can now build upon, giving investors a more complete toolkit for assessing the company's health and future prospects.

Unpacking the Numbers: A Regional Health Check

A deep dive into the Q1 2026 figures reveals distinct but complementary growth stories in each of Auna’s key markets.

In Peru, Auna's stronghold, the performance was marked by stability and high efficiency. The company’s flagship OncoSalud Peru segment continued its steady expansion, reaching 1,439,781 plan members, an increase of over 15,000 from the previous quarter. More impressively, capacity utilization in its Peruvian healthcare services network hit 76.3%, the highest level reported in the last five quarters. This suggests Auna is effectively managing its assets and maximizing patient throughput in a mature market. Surgeries also saw a significant jump to 5,851 thousand, a notable increase from any quarter in the preceding year.

Meanwhile, in Colombia, the story is one of scale and deepening integration. The number of 'Protected lives'—individuals covered under risk-sharing agreements—grew to 3,057,763. This metric, tracked only since late 2025, underscores Auna's success in expanding its managed care model within Colombia's highly regarded universal healthcare system. The network's facilities were busy, recording 80,716 total days of hospitalization and a robust capacity utilization of 79.3%, both figures representing five-quarter highs.

Perhaps the most compelling narrative comes from Mexico, where Auna appears to be executing a successful turnaround. After facing revenue challenges in 2025, the Q1 data indicates a sharp pivot towards high-value specialized services. The number of chemotherapy and radiotherapy sessions surged to 4,162, a staggering 78.4% increase from the 2,333 sessions delivered in the same quarter a year ago. This dramatic growth in oncology services points to a successful strategic focus on complex care in one of Latin America’s largest and most underpenetrated private healthcare markets.

A Strategic Focus on Specialized Care and Efficiency

The preliminary Q1 numbers are more than just a tally of procedures; they are a direct reflection of Auna's core strategy. The company has long stated its mission is to focus on complex diseases, which represent the highest healthcare spending, and the data shows this strategy in action. The growth in oncology treatments in Mexico and the continued expansion of OncoSalud in Peru are prime examples.

This focus on high-acuity care is paired with a clear drive for operational efficiency. Achieving capacity utilization rates of 76.3% in Peru and 79.3% in Colombia across a network of 31 facilities and 2,333 beds is no small feat. It demonstrates disciplined management and an ability to attract and serve a high volume of patients. This operational strength directly impacts financial health. For the full year 2025, Auna reported that its Oncology Medical Loss Ratio (MLR) fell to a record low of 48.5%, indicating greater profitability in its insurance segment.

The company is also investing in its physical infrastructure to support this growth. In Peru, Auna is partnering with the public entity EsSalud to construct the Torre Trecca in Lima, which is slated to become the country's largest outpatient facility. This public-private partnership not only expands Auna's footprint but also deeply embeds it within the national healthcare ecosystem, creating a durable competitive advantage.

By focusing on the most complex and costly areas of healthcare while simultaneously managing its assets with increasing efficiency, Auna is positioning itself as a critical component of the healthcare infrastructure in its operating regions. The latest key performance indicators suggest this dual strategy is not just an ambition but an operational reality that is actively delivering results.